International Stem Cell CORP 8K

International Stem Cell Corporation filed pro forma financials on Form 8-K to reflect the completed $25+ million sale of its Lifeline Cell Technology subsidiary to American Type Culture Collection, Inc., with the divested unit treated as discontinued operations and a significant gain on sale recognized.

International Stem Cell Corporation filed unaudited pro forma condensed consolidated financial statements reflecting the completed sale, on September 1, 2026, of 100% of the membership interests of its wholly owned subsidiary Lifeline Cell Technology, LLC to American Type Culture Collection, Inc. for an adjusted purchase price of approximately $25.7 million (including a fixed cash add-back and estimated working capital adjustment), resulting in net cash proceeds of about $21.7 million, a $2.6 million escrow receivable subject to release within 12 months, and an estimated after-tax gain of $21.9 million recorded directly to accumulated deficit, with Lifeline Cell Technology’s historical results to be presented as discontinued operations and International Stem Cell’s remaining operations continuing through Lifeline Skin Care, Inc. and its therapeutic R&D business.

Filing Facts

CIK

1355790

Ticker

-

Form

8K

Source Type

sec

Accession

0001683168-26-007007

Alert Tier

8